115 related articles for article (PubMed ID: 26561054)
21. Similarity of aberrant DNA methylation in Barrett's esophagus and esophageal adenocarcinoma.
Smith E; De Young NJ; Pavey SJ; Hayward NK; Nancarrow DJ; Whiteman DC; Smithers BM; Ruszkiewicz AR; Clouston AD; Gotley DC; Devitt PG; Jamieson GG; Drew PA
Mol Cancer; 2008 Oct; 7():75. PubMed ID: 18831746
[TBL] [Abstract][Full Text] [Related]
22. Dendritic cells engineered to secrete anti-DcR3 antibody augment cytotoxic T lymphocyte response against pancreatic cancer
Chen J; Guo XZ; Li HY; Zhao JJ; Xu WD
World J Gastroenterol; 2017 Feb; 23(5):817-829. PubMed ID: 28223726
[TBL] [Abstract][Full Text] [Related]
23. LINE-1 expression and retrotransposition in Barrett's esophagus and esophageal carcinoma.
Doucet-O'Hare TT; Rodić N; Sharma R; Darbari I; Abril G; Choi JA; Young Ahn J; Cheng Y; Anders RA; Burns KH; Meltzer SJ; Kazazian HH
Proc Natl Acad Sci U S A; 2015 Sep; 112(35):E4894-900. PubMed ID: 26283398
[TBL] [Abstract][Full Text] [Related]
24. Response to TNF-α Is Increasing Along with the Progression in Barrett's Esophagus.
Chemnitzer O; Götzel K; Maurer L; Dietrich A; Eichfeld U; Lyros O; Jansen-Winkeln B; Hoffmeister A; Gockel I; Thieme R
Dig Dis Sci; 2017 Dec; 62(12):3391-3401. PubMed ID: 29086334
[TBL] [Abstract][Full Text] [Related]
25. The esophagitis to adenocarcinoma sequence; the role of inflammation.
Kavanagh ME; O'Sullivan KE; O'Hanlon C; O'Sullivan JN; Lysaght J; Reynolds JV
Cancer Lett; 2014 Apr; 345(2):182-9. PubMed ID: 23994342
[TBL] [Abstract][Full Text] [Related]
26. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.
Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA
Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391
[TBL] [Abstract][Full Text] [Related]
27. Immunologic function of dendritic cells in esophageal cancer.
Yang W; Yu J
Dig Dis Sci; 2008 Jul; 53(7):1739-46. PubMed ID: 18080193
[TBL] [Abstract][Full Text] [Related]
28. Induction of cytotoxic T lymphocytes against human cancer cell lines using dendritic cell-tumor cell hybrids generated by a newly developed electrofusion technique.
Imura K; Ueda Y; Hayashi T; Itoh T; Shimizu K; Tamai H; Yano Y; Naito K; Kohara J; Nakane K; Matsuura Y; Takeda A; Takeda T; Kawai K; Yamagishi H
Int J Oncol; 2006 Sep; 29(3):531-9. PubMed ID: 16865268
[TBL] [Abstract][Full Text] [Related]
29. HLA-DR expression in tumor epithelium is an independent prognostic indicator in esophageal adenocarcinoma patients.
Dunne MR; Michielsen AJ; O'Sullivan KE; Cathcart MC; Feighery R; Doyle B; Watson JA; O'Farrell NJ; Ravi N; Kay E; Reynolds JV; Ryan EJ; O'Sullivan J
Cancer Immunol Immunother; 2017 Jul; 66(7):841-850. PubMed ID: 28315927
[TBL] [Abstract][Full Text] [Related]
30. MicroRNAs in Esophageal Adenocarcinoma: Functional Significance and Potential for the Development of New Molecular Disease Markers.
Bobryshev YV; Orekhov AN; Chistiakov DA
Curr Pharm Des; 2015; 21(23):3402-16. PubMed ID: 25758856
[TBL] [Abstract][Full Text] [Related]
31. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.
Nakamura M; Iwahashi M; Nakamori M; Ueda K; Ojima T; Naka T; Ishida K; Yamaue H
Oncology; 2005; 68(2-3):163-70. PubMed ID: 16006753
[TBL] [Abstract][Full Text] [Related]
32. In vitro and in vivo evaluations of human papillomavirus type 16 (HPV16)-derived peptide-loaded dendritic cells (DCs) with a CpG oligodeoxynucleotide (CpG-ODN) adjuvant as tumor vaccines for immunotherapy of cervical cancer.
Wang HL; Xu H; Lu WH; Zhu L; Yu YH; Hong FZ
Arch Gynecol Obstet; 2014 Jan; 289(1):155-62. PubMed ID: 23912529
[TBL] [Abstract][Full Text] [Related]
33. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.
Schnurr M; Galambos P; Scholz C; Then F; Dauer M; Endres S; Eigler A
Cancer Res; 2001 Sep; 61(17):6445-50. PubMed ID: 11522639
[TBL] [Abstract][Full Text] [Related]
34. Harnessing dendritic cells in cancer.
Apetoh L; Locher C; Ghiringhelli F; Kroemer G; Zitvogel L
Semin Immunol; 2011 Feb; 23(1):42-9. PubMed ID: 21295491
[TBL] [Abstract][Full Text] [Related]
35. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
36. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
[TBL] [Abstract][Full Text] [Related]
37. Esophageal Adenocarcinoma: Screening, Surveillance, and Management.
Mansour NM; Groth SS; Anandasabapathy S
Annu Rev Med; 2017 Jan; 68():213-227. PubMed ID: 27618753
[TBL] [Abstract][Full Text] [Related]
38. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients.
de Vries IJ; Lesterhuis WJ; Scharenborg NM; Engelen LP; Ruiter DJ; Gerritsen MJ; Croockewit S; Britten CM; Torensma R; Adema GJ; Figdor CG; Punt CJ
Clin Cancer Res; 2003 Nov; 9(14):5091-100. PubMed ID: 14613986
[TBL] [Abstract][Full Text] [Related]
39. Barrett's Esophagus and esophageal adenocarcinoma.
Bresalier RS
Annu Rev Med; 2009; 60():221-31. PubMed ID: 18783330
[TBL] [Abstract][Full Text] [Related]
40. Genes of the interleukin-18 pathway are associated with susceptibility to Barrett's esophagus and esophageal adenocarcinoma.
Babar M; Ryan AW; Anderson LA; Segurado R; Turner G; Murray LJ; Murphy SJ; Johnston BT; Comber H; Reynolds JV; McManus R
Am J Gastroenterol; 2012 Sep; 107(9):1331-41. PubMed ID: 22664470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
